제이엘케이

322510KOSDAQ소프트웨어 개발 및 공급업

40.5 / 100

Reference Date: 2026-04-13

Financial Score7.0 / 40

News Sentiment17.5 / 25

Momentum6.0 / 20

Disclosure10.0 / 15

AI Analysis: the high debt ratio poses financial risk, ROE is below the industry average. Plunged 23.6% over the past month, and news sentiment is positive.

Company InformationBased on 2025 Annual Report

Business Overview

JLK is a medical AI solution provider specializing in AI-based analysis of medical imaging, with a focus on stroke diagnosis and prognosis prediction. The company holds 78 global certifications and offers products such as MEDIHUB STROKE and cancer analysis solutions, driving growth in both domestic and international markets.

Number of Employees

87people

Average Salary

88.9M KRW

Score Calculation Basis

Detailed Financial Score

PER

—Industry Average 14.434.0Point

PBR

4.28Industry Average 1.280.0Point

3.3x industry avg (risky)

ROE

-30.01Industry Average 1.360.0Point

Well below industry avg

Debt Ratio

21.64Industry Average 7.930.0Point

2.7x industry avg (risky)

Trend 2023~20253.0 / 10 points

Revenue Growth Rate

3.0 / 3

Avg ▲45.6% (2-year basis)

Operating Profit Growth Rate

0.0 / 3

Avg ▼40.9% (2-year basis)

ROE Trend

0.0 / 4

Avg ROE -41.9% (improving, 3yr)

Detailed News Sentiment

6 totalPositive 3Neutral 0Negative 0Average Sentiment Score 90

Positive
제이엘케이, ‘비조영CT 뇌졸중 분석기기’ 美 시판허가
제이엘케이의 비조영CT 기반 뇌졸중 분석 솔루션 'JLK-NCCT'가 미국 FDA 시판허가를 획득하여 대혈관폐색 의심 환자 선별 및 초기 단계 신속 대응에 기여할 것으로 기대된다.
Positive
제이엘케이, 뇌졸중 분석 솔루션 美 FDA 510k 획득
제이엘케이의 비조영 CT 기반 뇌졸중 분석 솔루션 'JLK-NCCT'가 미국 FDA 510(k) Clearance를 획득하여 뇌졸중 진료 과정에서 의심 환자 식별 및 우선순위 설정 지원 AI 기술로서 임상적 가치를 인정받았다.
Positive
[바이오스냅] 제이엘케이, 'JLK-NCCT' 미 FDA 허가 획득
의료 AI 전문기업 제이엘케이의 비조영 CT 기반 뇌졸중 분석 솔루션 'JLK-NCCT'가 미국 FDA 510(k) Clearance를 획득하여 뇌졸중 진료 과정에서 AI 기술의 임상적 가치를 인정받았다.

Detailed Momentum

52-week position5.0Point

52w mid range (57%)

Current 6,880Won52-week high 9,00052-week low 4,045

1-month return0.0Point

1m -23.56% (strong drop)

Volume trend1.0Point

Volume dry-up

Detailed Disclosure

3 totalPositive 0Neutral 3Negative 0

Neutral정기주주총회결과2026-03-27
Neutral사업보고서 (2025.12)2026-03-19
Neutral감사보고서제출2026-03-19